Clinical trial
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens…
NCT00135395 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00135395 |
|---|---|
| Title | A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen |
| Official title | A Phase IIIb, Open -Label, Randomized Multi-center Study Comparing the Antiviral Efficacy, Safety, and Effect on Serum Lipids of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir, in Combination With Two Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTIs) in HIV-1 Infected Subjects… |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Atazanavir+ritonavir, Lopinavir+ritonavir |
| Enrollment | 200 |
| Start date | May 1, 2004 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Aug 26, 2005 |
| Last update posted | Feb 5, 2010 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: